Chronic obstructive pulmonary disease (COPD) often involves type 1 (T1) inflammation, but 40% of patients have T2 inflammation, which worsens outcomes. Dupilumab, targeting interleukin (IL)-4 and IL-13, shows promise in phase 3 trials. The new NOTUS trial 1 showed effectiveness in reducing exacerbations and improving lung function. However, its predominantly white population limits generalizability. Future research should include diverse populations and assess different therapies combined with dupilumab to improve outcomes.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- atopic dermatitis
- cystic fibrosis
- oxidative stress
- air pollution
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- ejection fraction
- systematic review
- chronic kidney disease
- clinical trial
- study protocol
- prognostic factors
- peritoneal dialysis
- type diabetes
- climate change
- current status
- phase iii
- metabolic syndrome
- big data
- patient reported outcomes
- drug delivery
- artificial intelligence
- glycemic control
- replacement therapy